DGAP-News: 4SC Presents Update on Phase II SHELTER trial with Oral Pan-HDAC Resminostat at the 2011 Gastrointestinal Cancer Symposium
(firmenpresse) - DGAP-News: 4SC AG / Key word(s): Miscellaneous
4SC Presents Update on Phase II SHELTER trial with Oral Pan-HDAC
Resminostat at the 2011 Gastrointestinal Cancer Symposium
21.01.2011 / 07:30
---------------------------------------------------------------------
Planegg-Martinsried, Germany, 21 January, 2011- 4SC (Frankfurt, Prime
Standard: VSC), a drug discovery and development company focused on
autoimmune and cancer indications, will today present a poster update on
the Phase II SHELTER trial in hepatocellular carcinoma (HCC) with the oral
pan-histone deacetylase (HDAC) inhibitor resminostat. The poster will be
presented by the lead investigator, Professor Dr. Michael Bitzer, at the
2011 Gastrointestinal Cancer Symposium (co-sponsored by the American
Society of Clinical Oncology - ASCO, the American Society of Radiation
Oncology - ASTRO and the Society of Surgical Oncology - SSO) on 20-21
January in San Francisco, USA.
Abstract: #71271:
Titel: Clinical update on the SHELTER study: A phase I/II trial of the HDAC
inhibitor resminostat in patients with sorafenib-resistant hepatocellular
carcinoma (HCC)
Session date and time: 21 January 2011, 11:45 am - 1.15 pm, Poster Session
B: Pancreas, Small Bowel and Hepatobiliary Tract
Poster Presenter: M. Bitzer, M. Horger, T. Ganten, M.P.Ebert, M.A. Woerns,
M.M. Dollinger, A. Kirsch, G. Gerken, M.E. Scheulen, R. Jankowsky, A. Mais,
B. Hauns, B. Hentsch, U.M. Lauer
- Ends -
About Resminostat (4SC-201)
Resminostat (4SC-201) is an oral pan-histone-deacetylase (HDAC) inhibitor.
HDAC inhibitors modify the DNA structure of tumour cells to cause their
differentiation and programmed cell death (apoptosis) and are therefore
considered to offer a mechanism of action that has the particular potential
to halt tumour progression and induce tumour regression. Resminostat is
currently also in a Phase II study as a second line treatment for advanced
hepatocellular carcinoma and KRAS-mutant colorectal patients and as a
third-line treatment in Hodgkin's lymphoma. In a completed Phase I trial in
patients with various different cancer types, stable disease was achieved
in over 50% of the patients, whilst the treatment was well tolerated and
showed a positive, differentiating pharmacological profile to other drugs
in this class.
About 4SC
4SC AG (ISIN DE0005753818) is a drug discovery and development company
focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a
small molecule, is currently in Phase II development in rheumatoid
arthritis and inflammatory bowel disease (IBD), for which positive results
from a Phase IIa study were recently reported. The company's lead oncology
compound, resminostat (4SC-201), a pan-histone deacetylase (HDAC)
inhibitor, is in Phase II trials in hepatocellular carcinoma, Hodgkin's
lymphoma and KRAS-mutant colorectal cancer. Two further oncology compounds,
4SC-203 and 4SC-205, are in Phase I studies. 4SC develops drug candidates
until proof-of-concept in order to generate value creating partnerships
with the pharmaceutical industry in return for advance and milestone
payments as well as royalties.
Founded in 1997, 4SC has 94 employees and has been listed on the Prime
Standard of the Frankfurt Stock Exchange since December 2005.
For further information, please visit www.4sc.com.
For more information please contact:
4SC AG
Yvonne Alexander
Investor&Public Relations
Tel.: +49 (0) 89 70 07 63 - 66
yvonne.alexander(at)4sc.com
MC Services (Europe)
Raimund Gabriel
Tel.: +49 (0) 89 21 02 28 - 30
raimund.gabriel(at)mc-services.eu
The Trout Group (USA)
Chad Rubin
Tel.: +1 646 378 2947
crubin(at)troutgroup.com
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
End of Corporate News
---------------------------------------------------------------------
21.01.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public(at)4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
109571 21.01.2011
Datum: 21.01.2011 - 07:30 Uhr
Sprache: Deutsch
News-ID 33036
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: 4SC Presents Update on Phase II SHELTER trial with Oral Pan-HDAC Resminostat at the 2011 Gastrointestinal Cancer Symposium"
steht unter der journalistisch-redaktionellen Verantwortung von
4SC AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
